Related references
Note: Only part of the references are listed.Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Su-Chen Fang et al.
JOURNAL OF CLINICAL PSYCHIATRY (2022)
Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study
Heidi Taipale et al.
LANCET PSYCHIATRY (2022)
The clinical relevance of gray matter atrophy and microstructural brain changes across the psychosis continuum
Faith M. Hanlon et al.
SCHIZOPHRENIA RESEARCH (2021)
Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia
Cheng-Yi Huang et al.
JAMA NETWORK OPEN (2021)
Predictors of suicide at time of diagnosis in schizophrenia spectrum disorder: A 20-year total population study in Ontario, Canada
Juveria Zaheer et al.
SCHIZOPHRENIA RESEARCH (2020)
Neuroprotective effects of the second generation antipsychotics
Alexander T. Chen et al.
SCHIZOPHRENIA RESEARCH (2019)
Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
Heidi Taipale et al.
SCHIZOPHRENIA RESEARCH (2018)
Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortality
Henry A. Nasrallah
SCHIZOPHRENIA RESEARCH (2018)
Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis
Maren Carbon et al.
WORLD PSYCHIATRY (2018)
Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
Jari Tiihonen et al.
JAMA PSYCHIATRY (2017)
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Eduard Parellada et al.
CNS DRUGS (2016)
The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies
Antonio Vita et al.
BIOLOGICAL PSYCHIATRY (2015)
Neuroinflammation and white matter pathology in schizophrenia: systematic review
Souhel Najjar et al.
SCHIZOPHRENIA RESEARCH (2015)
Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia A Randomized Clinical Trial
Kenneth L. Subotnik et al.
JAMA PSYCHIATRY (2015)
Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia
Robin Emsley et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies
A. Vita et al.
TRANSLATIONAL PSYCHIATRY (2012)
Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of Schizophrenia
Kenneth L. Subotnik et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Preventing the Second Episode: A Systematic Review and Meta-analysis of Psychosocial and Pharmacological Trials in First-Episode psychosis
Mario Alvarez-Jimenez et al.
SCHIZOPHRENIA BULLETIN (2011)
Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection
Robin Emsley et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Share Paper
